The percentage of patients who showed an increase in posterior RNP from baseline increased over time in all 3 groups , but at a faster rate in the sham group , resulting in statistically significant differences at every time point between months 3 ( 9.6 % vs. 18.5 % ; P = 0.016 ) and 24 ( 16.1 % vs. 37.6 % ; P < 0.0001 ) for ranibizumab 0.5 mg versus sham and from months 6 ( 12.3 % vs. 23.0 % ; P = 0.013 ) through 24 ( 15.0 % vs. 37.6 % ; P < 0.0001 ) for ranibizumab 0.3 mg .